Literature DB >> 15207426

Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years.

L Morgante1, G Basile, A Epifanio, E Spina, A Antonini, F Stocchi, E Di Rosa, G Martino, R Marconi, P La Spina, V Nicita-Mauro, A E Di Rosa.   

Abstract

This study was performed to assess whether patients with Parkinson's disease (PD)develop cognitive and psychiatric impairments more frequently during therapy with continuous subcutaneous apomorphine infusion (CAI) compared to the standard oral treatment. Thirty consecutive PD patients with severe motor fluctuations were included. Of them, 12 patients received the CAI treatment, while the remaining 18 continued the treatment with oral dopaminergic drugs. The two groups were evaluated with neuropsychological,psychiatric and motor tests at baseline and after two years. The off-awake daily duration and the levodopa dosage were significantly reduced in the patients infused with apomorphine.In comparison with the baseline evaluation, the neuropsychiatric assessment did not change in either of groups at the follow-up, except for a significant improvement of mood in the CAI treated group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207426     DOI: 10.1016/j.archger.2004.04.039

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr Suppl        ISSN: 0924-7947


  12 in total

Review 1.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

2.  A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation.

Authors:  Angelo Antonini; Ioannis U Isaias; Giorgia Rodolfi; Andrea Landi; Francesca Natuzzi; Chiara Siri; Gianni Pezzoli
Journal:  J Neurol       Date:  2010-10-23       Impact factor: 4.849

3.  Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.

Authors:  D De Gaspari; C Siri; A Landi; R Cilia; A Bonetti; F Natuzzi; L Morgante; C B Mariani; E Sganzerla; G Pezzoli; A Antonini
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

4.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 5.  The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review.

Authors:  Albert F G Leentjens
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

6.  Continuous subcutaneous apomorphine infusion in advanced Parkinson's disease: 10-year experience with 230 patients.

Authors:  Ángel Sesar; Gustavo Fernández-Pajarín; Begoña Ares; María Teresa Rivas; Alfonso Castro
Journal:  J Neurol       Date:  2017-03-31       Impact factor: 4.849

7.  Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.

Authors:  Sophie Drapier; Alexandre Eusebio; Bertrand Degos; Marc Vérin; Franck Durif; Jean Philippe Azulay; François Viallet; Tiphaine Rouaud; Caroline Moreau; Luc Defebvre; Valerie Fraix; Christine Tranchant; Karine Andre; Christine Brefel Courbon; Emmanuel Roze; David Devos
Journal:  J Neurol       Date:  2016-04-08       Impact factor: 4.849

Review 8.  Treatment of advanced Parkinson's disease.

Authors:  Juan C Giugni; Michael S Okun
Journal:  Curr Opin Neurol       Date:  2014-08       Impact factor: 5.710

Review 9.  Treatment of Parkinson's disease in the advanced stage.

Authors:  C Ossig; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2013-03-10       Impact factor: 3.575

Review 10.  Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review.

Authors:  Jens Volkmann; Alberto Albanese; Angelo Antonini; K Ray Chaudhuri; Carl E Clarke; Rob M A de Bie; Günther Deuschl; Karla Eggert; Jean-Luc Houeto; Jaime Kulisevsky; Dag Nyholm; Per Odin; Karen Østergaard; Werner Poewe; Pierre Pollak; Jose Martin Rabey; Olivier Rascol; Evzen Ruzicka; Michael Samuel; Hans Speelman; Olof Sydow; Francesc Valldeoriola; Chris van der Linden; Wolfgang Oertel
Journal:  J Neurol       Date:  2013-01-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.